Citation Export
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Jung, Keunok | - |
| dc.contributor.author | Ko, Deok Han | - |
| dc.contributor.author | Jang, Jeong Yun | - |
| dc.contributor.author | Kim, Young Rong | - |
| dc.contributor.author | Heo, Jung Yeon | - |
| dc.contributor.author | Kim, Yong Sung | - |
| dc.date.issued | 2024-01-01 | - |
| dc.identifier.issn | 2523-3548 | - |
| dc.identifier.uri | https://dspace.ajou.ac.kr/dev/handle/2018.oak/33727 | - |
| dc.description.sponsorship | This work was supported by the Samsung Future Technology Center (SRFCMA1802\u201009) and the Korea Health Technology R&D Project (HR22C173402) through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health and Welfare. | - |
| dc.language.iso | eng | - |
| dc.publisher | John Wiley and Sons Inc | - |
| dc.subject.mesh | CD8-Positive T-Lymphocytes | - |
| dc.subject.mesh | COVID-19 | - |
| dc.subject.mesh | Humans | - |
| dc.subject.mesh | Immunotherapy | - |
| dc.subject.mesh | Neoplasms | - |
| dc.subject.mesh | SARS-CoV-2 | - |
| dc.title | Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy | - |
| dc.type | Letter | - |
| dc.citation.endPage | 177 | - |
| dc.citation.startPage | 173 | - |
| dc.citation.title | Cancer Communications | - |
| dc.citation.volume | 44 | - |
| dc.identifier.bibliographicCitation | Cancer Communications, Vol.44, pp.173-177 | - |
| dc.identifier.doi | 10.1002/cac2.12497 | - |
| dc.identifier.pmid | 37856250 | - |
| dc.identifier.scopusid | 2-s2.0-85174270857 | - |
| dc.identifier.url | https://onlinelibrary.wiley.com/journal/25233548 | - |
| dc.description.isoa | true | - |
| dc.subject.subarea | Oncology | - |
| dc.subject.subarea | Cancer Research | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
